Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study.
Mok
Chi Chiu
CC
Department of Medicine, Tuen Mun Hospital, New Territories, Hong Kong, China. ccmok@netvigator.com
Lau
Chak Sing
CS
Wong
Raymond W S
RW
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000974:Antibodies, Antinuclear / Q000276:immunology; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000523:psychology*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000209:etiology*
D000893:Anti-Inflammatory Agents; D000974:Antibodies, Antinuclear; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone